Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 9/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.32 |
| ▸ | TNF | P01375 | 2/20 | 0.32 |
| ▸ | KCNJ5 | P48544 | 3/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.31 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26856115 | 0.85 | CYP19A1 (0.36) | IRAK4CYP19A1KCNJ5 | |
| SCHEMBL26854569 | 0.83 | CREBBP (0.35) | IRAK4CREBBPCYP19A1KCNJ5 | |
| SCHEMBL26854653 | 0.83 | CREBBP (0.35) | IRAK4CREBBPCYP19A1KCNJ5 | |
| SCHEMBL29544363 | 0.79 | ACHE (0.35) | IRAK4CREBBPCYP19A1KCNJ5CYP11B2 | |
| SCHEMBL4351000 | 0.76 | ACHE (0.44) | IRAK4CREBBPCYP19A1CYP11B2 | |
| SCHEMBL19182637 | 0.74 | ACHE (0.52) | CREBBPCYP19A1CYP11B2 | |
| SCHEMBL25014958 | 0.73 | CYP19A1 (0.38) | CYP19A1CYP11B2ARABCC9KCNJ11 | |
| SCHEMBL21214990 | 0.70 | KDM4E (0.36) | IRAK4CREBBP | |
| SCHEMBL17395099 | 0.70 | IRAK4 (0.38) | IRAK4CREBBPCYP19A1TNFCYP11B2 | |
| SCHEMBL6985537 | 0.69 | CYP19A1 (0.38) | IRAK4CYP19A1CYP11B2AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365584-A1 | HETEROCYCLIC PERICONDENSED CDC7 KINASE INHIBITORS FOR THE TREATMENT OF CANCER | SCHRÖDINGER, INC. | 2023-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365584-A1 | HETEROCYCLIC PERICONDENSED CDC7 KINASE INHIBITORS FOR THE TREATMENT OF CANCER | CDC7, BUB1B, CDK7 | IRAK4 1832/4885CREBBP 2275/4885CYP19A1 2404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.